Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition
Background Elevated serum leptin (S‐leptin) levels have been reported in patients with end‐stage renal disease (ESRD). Apart from the decreased glomerular filtration rate (GFR), body composition and inflammation may affect leptin levels in ESRD. Leptin circulates both free of and bound to soluble le...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical investigation 2002-11, Vol.32 (11), p.811-817 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 817 |
|---|---|
| container_issue | 11 |
| container_start_page | 811 |
| container_title | European journal of clinical investigation |
| container_volume | 32 |
| creator | Pecoits-Filho, R. Nordfors, L. Heimbürger, O. Lindholm, B. Anderstam, B. Marchlewska, A. Stenvinkel, P. |
| description | Background Elevated serum leptin (S‐leptin) levels have been reported in patients with end‐stage renal disease (ESRD). Apart from the decreased glomerular filtration rate (GFR), body composition and inflammation may affect leptin levels in ESRD. Leptin circulates both free of and bound to soluble leptin receptors (sOB‐R), which are the main determinants of leptin activity and have not been described in ESRD until now.
Design To analyze the association between S‐leptin, sOB‐R, and inflammation and body composition, we studied 149 (62% males) normal weight (BMI 24·7 ± 0·4 kg m−2) ESRD patients (51 ± 1 years old) shortly before the start of dialysis (GFR 7·0 ± 0·2 mL min−1). sOB‐R and plasma interleukin‐6 (IL‐6; n= 113) levels were evaluated using ELISA, S‐leptin using RIA, and body composition was assessed by X‐ray absorptiometry (n = 139). Forty‐one healthy subjects age (51 ± 1 years), BMI (23·6 ± 0·5 kg m−2) and gender‐matched (59% males) were used as controls.
Results Median S‐leptin was higher in the ESRD patients (10·0 ng mL−1) compared with the controls (3·9 ng mL−1) (P |
| doi_str_mv | 10.1046/j.1365-2362.2002.01063.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_592026</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>262368571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5273-f5013bfbe32fe8cc7d5625786bae5019a86518bea8126bb8fd23e3f4a2d43b3</originalsourceid><addsrcrecordid>eNqNkd-L1DAQx4so3nr6L0gR9K1rMmnTVPBBlvsFpz6c4GNI2qmXvbSpScvu_vemu-su-CQEMpn5fCfDfJMkpWRJSc4_rpeU8SIDxmEJhMCSUMLZcvssWZwKz5MFITTPoCrhInkVwpoQIiiDl8kFhRwYA7pIdg_OTtpianEYTZ96rGPgfEhV36QB_dT9LcWDfZOFUf3CyPXKpo0JqAJ-ik-rRuP68GiGdGPGx0i3VnXdPrvvpV2zS2vXDS6YOfk6edEqG_DN8b5MHq6vfqxus_vvN3erL_dZXUDJsrYglOlWI4MWRV2XTcGhKAXXCmOpUoIXVGhUggLXWrQNMGRtrqDJmWaXSXboGjY4TFoO3nTK76RTRh5TTzFCWVRAgEf-w4EfvPs9YRhlZ0KN1qoe3RRkCZwLkbMIvvsHXLvJx6UESauKAuFQRUgcoNq7EDy2p_8pkbOTci1nw-RsmJydlHsn5TZK3x77T7rD5iw8WheB90dAhVrZ1qu-NuHM5YRyQuZBPx-4jbG4--8B5NXqbo7OGzRhxO1Jr_yT5CUrC_nz2438ylklbksqr9kfL4HKUQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199120629</pqid></control><display><type>article</type><title>Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Pecoits-Filho, R. ; Nordfors, L. ; Heimbürger, O. ; Lindholm, B. ; Anderstam, B. ; Marchlewska, A. ; Stenvinkel, P.</creator><creatorcontrib>Pecoits-Filho, R. ; Nordfors, L. ; Heimbürger, O. ; Lindholm, B. ; Anderstam, B. ; Marchlewska, A. ; Stenvinkel, P.</creatorcontrib><description><![CDATA[Background Elevated serum leptin (S‐leptin) levels have been reported in patients with end‐stage renal disease (ESRD). Apart from the decreased glomerular filtration rate (GFR), body composition and inflammation may affect leptin levels in ESRD. Leptin circulates both free of and bound to soluble leptin receptors (sOB‐R), which are the main determinants of leptin activity and have not been described in ESRD until now.
Design To analyze the association between S‐leptin, sOB‐R, and inflammation and body composition, we studied 149 (62% males) normal weight (BMI 24·7 ± 0·4 kg m−2) ESRD patients (51 ± 1 years old) shortly before the start of dialysis (GFR 7·0 ± 0·2 mL min−1). sOB‐R and plasma interleukin‐6 (IL‐6; n= 113) levels were evaluated using ELISA, S‐leptin using RIA, and body composition was assessed by X‐ray absorptiometry (n = 139). Forty‐one healthy subjects age (51 ± 1 years), BMI (23·6 ± 0·5 kg m−2) and gender‐matched (59% males) were used as controls.
Results Median S‐leptin was higher in the ESRD patients (10·0 ng mL−1) compared with the controls (3·9 ng mL−1) (P < 0·001). The median sOB‐R did not differ significantly between the ESRD patients (44 U mL−1) and the controls (37 U mL−1). Thus, the sOB‐R/S‐leptin ratio was lower in the ESRD patients (9·5 ± 1·2 vs. 12·3 ± 1·8; P < 0·01) than the controls. A negative correlation was observed between S‐leptin and sOB‐R (Rho = −0·42; P < 0·0001) in the ESRD patients, a positive correlation was observed between lean body mass and the sOB‐R/S‐leptin ratio (Rho = 0·33, P = 0·0001) whereas fat mass was negatively correlated to both sOB‐R (Rho = −0·26, P = 0·002), and the sOB‐R/S‐leptin ratio (Rho = −0·62, P < 0·0001). Positive correlations were observed between IL‐6 and S‐leptin (Rho = 0·19; P < 0·05) and weak but significant body fat mass (Rho = 0·20; P < 0·05), respectively.
Conclusions This study demonstrates that despite markedly elevated S‐leptin levels in the ESRD patients, sOB‐R did not differ from the controls. In view of the anorexigenic and pro‐atherogenic effects of leptin, further elucidation of the consequences of free bioactive leptin in the development of complications such as malnutrition and cardiovascular disease in ESRD patients is required.]]></description><identifier>ISSN: 0014-2972</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1046/j.1365-2362.2002.01063.x</identifier><identifier>PMID: 12423321</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Biological and medical sciences ; Body Composition ; Case-Control Studies ; Diabetes Mellitus - blood ; Diabetes Mellitus - immunology ; Diabetes Mellitus - metabolism ; end-stage renal disease ; Female ; Humans ; inflammation ; Interleukin-6 - blood ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - immunology ; Kidney Failure, Chronic - metabolism ; leptin ; Leptin - blood ; Male ; Medical sciences ; Middle Aged ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Prospective Studies ; Receptors, Cell Surface - blood ; Receptors, Leptin ; Renal failure ; soluble leptin receptors ; Statistics, Nonparametric</subject><ispartof>European journal of clinical investigation, 2002-11, Vol.32 (11), p.811-817</ispartof><rights>2003 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Nov 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5273-f5013bfbe32fe8cc7d5625786bae5019a86518bea8126bb8fd23e3f4a2d43b3</citedby><cites>FETCH-LOGICAL-c5273-f5013bfbe32fe8cc7d5625786bae5019a86518bea8126bb8fd23e3f4a2d43b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2362.2002.01063.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2362.2002.01063.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14016003$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12423321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:1938256$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Pecoits-Filho, R.</creatorcontrib><creatorcontrib>Nordfors, L.</creatorcontrib><creatorcontrib>Heimbürger, O.</creatorcontrib><creatorcontrib>Lindholm, B.</creatorcontrib><creatorcontrib>Anderstam, B.</creatorcontrib><creatorcontrib>Marchlewska, A.</creatorcontrib><creatorcontrib>Stenvinkel, P.</creatorcontrib><title>Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description><![CDATA[Background Elevated serum leptin (S‐leptin) levels have been reported in patients with end‐stage renal disease (ESRD). Apart from the decreased glomerular filtration rate (GFR), body composition and inflammation may affect leptin levels in ESRD. Leptin circulates both free of and bound to soluble leptin receptors (sOB‐R), which are the main determinants of leptin activity and have not been described in ESRD until now.
Design To analyze the association between S‐leptin, sOB‐R, and inflammation and body composition, we studied 149 (62% males) normal weight (BMI 24·7 ± 0·4 kg m−2) ESRD patients (51 ± 1 years old) shortly before the start of dialysis (GFR 7·0 ± 0·2 mL min−1). sOB‐R and plasma interleukin‐6 (IL‐6; n= 113) levels were evaluated using ELISA, S‐leptin using RIA, and body composition was assessed by X‐ray absorptiometry (n = 139). Forty‐one healthy subjects age (51 ± 1 years), BMI (23·6 ± 0·5 kg m−2) and gender‐matched (59% males) were used as controls.
Results Median S‐leptin was higher in the ESRD patients (10·0 ng mL−1) compared with the controls (3·9 ng mL−1) (P < 0·001). The median sOB‐R did not differ significantly between the ESRD patients (44 U mL−1) and the controls (37 U mL−1). Thus, the sOB‐R/S‐leptin ratio was lower in the ESRD patients (9·5 ± 1·2 vs. 12·3 ± 1·8; P < 0·01) than the controls. A negative correlation was observed between S‐leptin and sOB‐R (Rho = −0·42; P < 0·0001) in the ESRD patients, a positive correlation was observed between lean body mass and the sOB‐R/S‐leptin ratio (Rho = 0·33, P = 0·0001) whereas fat mass was negatively correlated to both sOB‐R (Rho = −0·26, P = 0·002), and the sOB‐R/S‐leptin ratio (Rho = −0·62, P < 0·0001). Positive correlations were observed between IL‐6 and S‐leptin (Rho = 0·19; P < 0·05) and weak but significant body fat mass (Rho = 0·20; P < 0·05), respectively.
Conclusions This study demonstrates that despite markedly elevated S‐leptin levels in the ESRD patients, sOB‐R did not differ from the controls. In view of the anorexigenic and pro‐atherogenic effects of leptin, further elucidation of the consequences of free bioactive leptin in the development of complications such as malnutrition and cardiovascular disease in ESRD patients is required.]]></description><subject>Biological and medical sciences</subject><subject>Body Composition</subject><subject>Case-Control Studies</subject><subject>Diabetes Mellitus - blood</subject><subject>Diabetes Mellitus - immunology</subject><subject>Diabetes Mellitus - metabolism</subject><subject>end-stage renal disease</subject><subject>Female</subject><subject>Humans</subject><subject>inflammation</subject><subject>Interleukin-6 - blood</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - immunology</subject><subject>Kidney Failure, Chronic - metabolism</subject><subject>leptin</subject><subject>Leptin - blood</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Prospective Studies</subject><subject>Receptors, Cell Surface - blood</subject><subject>Receptors, Leptin</subject><subject>Renal failure</subject><subject>soluble leptin receptors</subject><subject>Statistics, Nonparametric</subject><issn>0014-2972</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd-L1DAQx4so3nr6L0gR9K1rMmnTVPBBlvsFpz6c4GNI2qmXvbSpScvu_vemu-su-CQEMpn5fCfDfJMkpWRJSc4_rpeU8SIDxmEJhMCSUMLZcvssWZwKz5MFITTPoCrhInkVwpoQIiiDl8kFhRwYA7pIdg_OTtpianEYTZ96rGPgfEhV36QB_dT9LcWDfZOFUf3CyPXKpo0JqAJ-ik-rRuP68GiGdGPGx0i3VnXdPrvvpV2zS2vXDS6YOfk6edEqG_DN8b5MHq6vfqxus_vvN3erL_dZXUDJsrYglOlWI4MWRV2XTcGhKAXXCmOpUoIXVGhUggLXWrQNMGRtrqDJmWaXSXboGjY4TFoO3nTK76RTRh5TTzFCWVRAgEf-w4EfvPs9YRhlZ0KN1qoe3RRkCZwLkbMIvvsHXLvJx6UESauKAuFQRUgcoNq7EDy2p_8pkbOTci1nw-RsmJydlHsn5TZK3x77T7rD5iw8WheB90dAhVrZ1qu-NuHM5YRyQuZBPx-4jbG4--8B5NXqbo7OGzRhxO1Jr_yT5CUrC_nz2438ylklbksqr9kfL4HKUQ</recordid><startdate>200211</startdate><enddate>200211</enddate><creator>Pecoits-Filho, R.</creator><creator>Nordfors, L.</creator><creator>Heimbürger, O.</creator><creator>Lindholm, B.</creator><creator>Anderstam, B.</creator><creator>Marchlewska, A.</creator><creator>Stenvinkel, P.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>200211</creationdate><title>Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition</title><author>Pecoits-Filho, R. ; Nordfors, L. ; Heimbürger, O. ; Lindholm, B. ; Anderstam, B. ; Marchlewska, A. ; Stenvinkel, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5273-f5013bfbe32fe8cc7d5625786bae5019a86518bea8126bb8fd23e3f4a2d43b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Biological and medical sciences</topic><topic>Body Composition</topic><topic>Case-Control Studies</topic><topic>Diabetes Mellitus - blood</topic><topic>Diabetes Mellitus - immunology</topic><topic>Diabetes Mellitus - metabolism</topic><topic>end-stage renal disease</topic><topic>Female</topic><topic>Humans</topic><topic>inflammation</topic><topic>Interleukin-6 - blood</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - immunology</topic><topic>Kidney Failure, Chronic - metabolism</topic><topic>leptin</topic><topic>Leptin - blood</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Prospective Studies</topic><topic>Receptors, Cell Surface - blood</topic><topic>Receptors, Leptin</topic><topic>Renal failure</topic><topic>soluble leptin receptors</topic><topic>Statistics, Nonparametric</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pecoits-Filho, R.</creatorcontrib><creatorcontrib>Nordfors, L.</creatorcontrib><creatorcontrib>Heimbürger, O.</creatorcontrib><creatorcontrib>Lindholm, B.</creatorcontrib><creatorcontrib>Anderstam, B.</creatorcontrib><creatorcontrib>Marchlewska, A.</creatorcontrib><creatorcontrib>Stenvinkel, P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pecoits-Filho, R.</au><au>Nordfors, L.</au><au>Heimbürger, O.</au><au>Lindholm, B.</au><au>Anderstam, B.</au><au>Marchlewska, A.</au><au>Stenvinkel, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2002-11</date><risdate>2002</risdate><volume>32</volume><issue>11</issue><spage>811</spage><epage>817</epage><pages>811-817</pages><issn>0014-2972</issn><eissn>1365-2362</eissn><abstract><![CDATA[Background Elevated serum leptin (S‐leptin) levels have been reported in patients with end‐stage renal disease (ESRD). Apart from the decreased glomerular filtration rate (GFR), body composition and inflammation may affect leptin levels in ESRD. Leptin circulates both free of and bound to soluble leptin receptors (sOB‐R), which are the main determinants of leptin activity and have not been described in ESRD until now.
Design To analyze the association between S‐leptin, sOB‐R, and inflammation and body composition, we studied 149 (62% males) normal weight (BMI 24·7 ± 0·4 kg m−2) ESRD patients (51 ± 1 years old) shortly before the start of dialysis (GFR 7·0 ± 0·2 mL min−1). sOB‐R and plasma interleukin‐6 (IL‐6; n= 113) levels were evaluated using ELISA, S‐leptin using RIA, and body composition was assessed by X‐ray absorptiometry (n = 139). Forty‐one healthy subjects age (51 ± 1 years), BMI (23·6 ± 0·5 kg m−2) and gender‐matched (59% males) were used as controls.
Results Median S‐leptin was higher in the ESRD patients (10·0 ng mL−1) compared with the controls (3·9 ng mL−1) (P < 0·001). The median sOB‐R did not differ significantly between the ESRD patients (44 U mL−1) and the controls (37 U mL−1). Thus, the sOB‐R/S‐leptin ratio was lower in the ESRD patients (9·5 ± 1·2 vs. 12·3 ± 1·8; P < 0·01) than the controls. A negative correlation was observed between S‐leptin and sOB‐R (Rho = −0·42; P < 0·0001) in the ESRD patients, a positive correlation was observed between lean body mass and the sOB‐R/S‐leptin ratio (Rho = 0·33, P = 0·0001) whereas fat mass was negatively correlated to both sOB‐R (Rho = −0·26, P = 0·002), and the sOB‐R/S‐leptin ratio (Rho = −0·62, P < 0·0001). Positive correlations were observed between IL‐6 and S‐leptin (Rho = 0·19; P < 0·05) and weak but significant body fat mass (Rho = 0·20; P < 0·05), respectively.
Conclusions This study demonstrates that despite markedly elevated S‐leptin levels in the ESRD patients, sOB‐R did not differ from the controls. In view of the anorexigenic and pro‐atherogenic effects of leptin, further elucidation of the consequences of free bioactive leptin in the development of complications such as malnutrition and cardiovascular disease in ESRD patients is required.]]></abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>12423321</pmid><doi>10.1046/j.1365-2362.2002.01063.x</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2972 |
| ispartof | European journal of clinical investigation, 2002-11, Vol.32 (11), p.811-817 |
| issn | 0014-2972 1365-2362 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_592026 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Biological and medical sciences Body Composition Case-Control Studies Diabetes Mellitus - blood Diabetes Mellitus - immunology Diabetes Mellitus - metabolism end-stage renal disease Female Humans inflammation Interleukin-6 - blood Kidney Failure, Chronic - blood Kidney Failure, Chronic - immunology Kidney Failure, Chronic - metabolism leptin Leptin - blood Male Medical sciences Middle Aged Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Prospective Studies Receptors, Cell Surface - blood Receptors, Leptin Renal failure soluble leptin receptors Statistics, Nonparametric |
| title | Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T06%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Soluble%20leptin%20receptors%20and%20serum%20leptin%20in%20end-stage%20renal%20disease:%20relationship%20with%20inflammation%20and%20body%20composition&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Pecoits-Filho,%20R.&rft.date=2002-11&rft.volume=32&rft.issue=11&rft.spage=811&rft.epage=817&rft.pages=811-817&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1046/j.1365-2362.2002.01063.x&rft_dat=%3Cproquest_swepu%3E262368571%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199120629&rft_id=info:pmid/12423321&rfr_iscdi=true |